VERBASCOSIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H36O15
Molecular Weight	624.5871
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCC3=CC=C(O)C(O)=C3)O[C@H](CO)[C@H]2OC(=O)\C=C\C4=CC=C(O)C(O)=C4)[C@H](O)[C@H](O)[C@H]1O

InChI

InChIKey=FBSKJMQYURKNSU-ZLSOWSIRSA-N

InChI=1S/C29H36O15/c1-13-22(36)23(37)24(38)29(41-13)44-27-25(39)28(40-9-8-15-3-6-17(32)19(34)11-15)42-20(12-30)26(27)43-21(35)7-4-14-2-5-16(31)18(33)10-14/h2-7,10-11,13,20,22-34,36-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28+,29-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C29H36O15
Molecular Weight	624.5871
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22147269 | https://clinicaltrials.gov/ct2/show/NCT02662283 | https://www.ncbi.nlm.nih.gov/pubmed/29054705

Acteoside (verbsacoside) is the one of the main active phenylethanoid glycosides from Cistanche deserticola, Lantana camara and some others herbs. It is known to have antioxidant and neuroprotective activity, and herbs containing it are used to enhance memory and can be studied for the treatment of Alzheimer's disease. It is known, that amyloid fibrils accumulation in cerebral can easily lead to neurodegenerative disorders. Acteoside has been reported to inhibit Aβ42 aggregation by activating nuclear translocation of the transcription factor NF-E2-related factor 2 (Nrf2), increasing heme oxygenase-1 (HO-1) expression. It has also been shown that acteoside could decrease nitric oxide synthase (NOS) activity and caspase-3 expression. Acteoside is a natural antioxidant product unlike other anti-tumor compounds, is an inhibitor of protein kinase C (PKC). In addition Reh-acteoside, a general acteoside of Rehmannia leaves was studied in phase 2/3 clinical trials for patients with IgA nephropathy.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Protein kinase C (PKC) 44 Target ID: CHEMBL2094266 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1812212	Inhibitor 8504		25.0 µM [Ki]
Nuclear factor erythroid 2-related factor 2 15 Target ID: Q16236 Gene ID: 4780.0 Gene Symbol: NFE2L2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/22147269	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
IGA nephropathy 1 Sources: https://clinicaltrials.gov/ct2/show/NCT02662283	Primary		Phase III 665	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252		inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
mCYP2E1 1 CYP2A6 879 CYP1A1 132 CYP19A1 429 CYP1A2 2153 CYP1B1 32	CYPs 33 UGT1A7 249 UGT1A8 323 BCRP 697 P-gp 2052 UGT1A10 331 MRP2 252	rGST-alpha 1

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/31212689/	moderate [IC50 24 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/31212689/	no
CYP1A1 272	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/31212689/	unlikely [IC50 350 uM]
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/31212689/	weak [IC50 135 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/31212689/	weak [IC50 76 uM]
CYP1B1 93	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/31212689/	weak [IC50 86 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/31212689/	weak [IC50 96 uM]
CYP2C19 2141	activator 342 Sources: https://pubmed.ncbi.nlm.nih.gov/31212689/	weak
mCYP2E1 2	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/14672760/	yes
rGST-alpha 1	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/16649555/	yes

Drug as victim

Target	Modality	Activity
UGT1A10 331	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31212689/	likely
UGT1A7 249	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31212689/	likely
UGT1A8 323	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31212689/	likely
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/29687721/	no
CYPs 33	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31212689/	no
MRP2 252	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/29687721/	no
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/33184029/ \| https://pubmed.ncbi.nlm.nih.gov/29687721/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/720551#sid=85201029

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P003ARN	https://www.1pchem.com/search?query=1P003ARN
A2B Chem	AB53123	http://a2bchem.com/prod/AB53123
AK Scientific	V1534	https://aksci.com/item_detail.php?cat=V1534
Alfa Chemistry	ACM22323520	http://www.alfa-chemistry.com/search.aspx?q=ACM22323520
Ambeed	A119193	http://www.ambeed.com/search/Search.html?keyword=A119193
AstaTech	41627	http://astatechinc.com/CPSResult.php?CRNO=41627
AstaTech	44132	http://astatechinc.com/CPSResult.php?CRNO=44132
Biopurify Phytochemicals	BP0124	https://www.phytopurify.com/search.do?a=s&searchtype=3&psize=10&q=BP0124&searchhtmp=simplesearch&t=1
BLD Pharm	BD134970	http://www.bldpharm.com/search/Search.html?keyword=BD134970
BOC Sciences	22323-52-0	http://www.bocsci.com/description.asp?cas=22323-52-0
Chem Scene	CS-2624	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-2624
Combi-Blocks	QV-0462	http://www.combi-blocks.com/cgi-bin/find.cgi?QV-0462
eMolecules	30512773	https://orderbb.emolecules.com/search/#?query=30512773
eMolecules	43445639	https://orderbb.emolecules.com/search/#?query=43445639
eMolecules	50894955	https://orderbb.emolecules.com/search/#?query=50894955
eMolecules	95715841	https://orderbb.emolecules.com/search/#?query=95715841
KeyOrganics	AS-75167	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-75167
mcule	MCULE-6138465280	https://mcule.com/MCULE-6138465280/
MedChem Express	HY-N0021	https://www.medchemexpress.com/search.html?q=HY-N0021&ft=&fa=&fp=
Molnova	M18894	https://www.molnova.com/en/serch-list.html?keywords=M18894
MolPort	MolPort-001-740-227	https://www.molport.com/shop/molecule-link/MolPort-001-740-227
MolPort	MolPort-006-069-350	https://www.molport.com/shop/molecule-link/MolPort-006-069-350
TargetMol	BBP00491	https://www.targetmol.com/search?keyword=BBP00491
TargetMol	T3375	https://www.targetmol.com/search?keyword=T3375
W&J PharmaChem	50A169811	http://wjpharmachem.com/new/searcht.php?keyword=50A169811

PubMed

Title	Date	PubMed
Resveratrol induces long-lasting IL-8 expression and peculiar EGFR activation/distribution in human keratinocytes: mechanisms and implications for skin administration.	2013	23527233
Modulation of human keratinocyte responses to solar UV by plant polyphenols as a basis for chemoprevention of non-melanoma skin cancers.	2013	23210792
Plant polyphenols regulate chemokine expression and tissue repair in human keratinocytes through interaction with cytoplasmic and nuclear components of epidermal growth factor receptor system.	2012-02-15	21967610
Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFκB and AhR and EGFR-ERK pathway.	2011-09-01	21756928
In vitro antifungal activities of amphotericin B in combination with acteoside, a phenylethanoid glycoside from Colebrookea oppositifolia.	2011-09	21474610
Antioxidant and signal modulation properties of plant polyphenols in controlling vascular inflammation.	2011-05-11	21371465
Natural antioxidants synergistically enhance the anticancer potential of AP9-cd, a novel lignan composition from Cedrus deodara in human leukemia HL-60 cells.	2010-12-05	20932957
Acteoside inhibits human promyelocytic HL-60 leukemia cell proliferation via inducing cell cycle arrest at G0/G1 phase and differentiation into monocyte.	2007-09	17634406
The inhibitory effect of phenylpropanoid glycosides and iridoid glucosides on free radical production and beta2 integrin expression in human leucocytes.	2006-01	16393473
Protective effect of acteoside on carbon tetrachloride-induced hepatotoxicity.	2004-01-09	14672760
HIV gp41 binding phenolic components from Fraxinus sieboldiana var. angustata.	2002-11	12451497
HIV-1 integrase inhibitory phenylpropanoid glycosides from Clerodendron trichotomum.	2001-08	11534758

Patents

Sample Use Guides

In Vivo Use Guide

Oral take reh-acteoside (0.4g bid) for 8 weeks

Route of Administration: Oral

In Vitro Use Guide

Acteoside treatment resulted in nuclear translocation of the transcription factor NF-E2-related factor 2 (Nrf2). Acteoside activated both ERK and PI3 K/Akt, and treatments with the specific ERK inhibitor PD98059, the PI3 K inhibitor LY294002, and the specific Nrf2 siRNA suppressed the acteoside-induced HO-1 expression. The PC12 cells transfected with Nrf2-siRNA (siNrf2) were treated with acteoside (30 uM), and the level of Nrf2 protein was then determined by Western blotting. Acteoside induced the accumulation of Nrf2 in the nuclei.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:39:59 GMT 2025` Edited by `admin` on `Mon Mar 31 22:39:59 GMT 2025`
Record UNII	3TGX09BD5B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NSC-603831

Preferred Name

English

VERBASCOSIDE

Official Name

English

TJC-160

Code

English

RUSSETINOL

Common Name

English

KUSAGININ

Common Name

English

STEREOSPERMIN

Common Name

English

VERBASCOSIDE [USP-RS]

Common Name

English

.BETA.-D-GLUCOPYRANOSIDE, 2-(3,4-DIHYDROXYPHENYL)ETHYL 3-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-, 4-((2E)-3-(3,4-DIHYDROXYPHENYL)-2-PROPENOATE)

Systematic Name

English

ACTEOSIDE

Common Name

English

Classification Tree Code System Code

DSLD

3474 (Number of products:7)